Drug Name:
HYCET CII
Generic Name and Formulations:
Hydrocodone bitartrate 7.5mg, acetaminophen 325mg; per 15mL soln; contains alcohol (7%); tropical fruit punch flavor.
Company:
Pharmaceutical Associates, Inc.
Therapeutic Use:
Indications for HYCET:
Moderate to moderately severe pain.
Adult:
Administer with calibrated measuring device. ≥14yrs (≥46kg): 15mL every 4–6 hours as needed; max 90mL/day.
Children:
<2yrs: not recommended. Administer with calibrated measuring device. Dosing should be based on weight (0.27mL/kg). 2–3yrs (12–15kg): 3.75mL. 4–6yrs (16–22kg): 5mL. 7–9yrs (23–31kg): 7.5mL. 10–13yrs (32–45kg): 10mL. All: give every 4–6 hours as needed; max: 6 doses/day.
Warnings/Precautions:
Head injury. Increased intracranial pressure. Acute abdomen. Impaired renal, hepatic, thyroid, pulmonary, or adrenocortical function. Severe renal or hepatic disease: monitor liver and renal function tests periodically. GI or GU obstruction. Post-op use. Drug abusers. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C) (neonatal withdrawal syndrome). Nursing mothers: not recommended.
Pharmacological Class:
Opioid + analgesic.
Interactions:
Potentiation with alcohol, other CNS depressants (eg, antihistamines, antipsychotics, antianxiety drugs). May potentiate or be potentiated by MAOIs, tricyclic antidepressants.
Adverse Reactions:
CNS/respiratory/circulatory depression, hypotension, dizziness, GI upset, constipation, urinary retention, rash; hepatotoxicity (overdosage).
How Supplied:
Soln—473mL (1 pint)
Sign Up for Free e-newsletters
ONA Articles
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Shifting Dynamics of Social Support After a Cancer Diagnosis
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |